DCGI Seeking More Data For Granting Emergency Use Authorisation Won’t Impact Timeline For Vaccine Roll-Out: Govt

New Delhi : The applications of Bharat Biotech, Serum Institute and Pfizer seeking emergency use authorisation for their COVID-19 vaccines are being examined, the Centre said on Tuesday asserting that drug regulator DCGI seeking more data from these companies will not impact the vaccine-roll out timeline.

“These applications filed with the Drugs Controller General of India are being examined by the subject expert committee on COVID-19 of CDSCO for emergency use authorisation,” NITI Aayog member (health) Dr V K Paul said.

“This situation was factored-in from before as it is emergency use authorisation. There should be more than reasonable satisfaction about the safety, immunogenicity and effectiveness of the vaccine,” he told reporters when asked about DCGI seeking more information from the companies for grant of emergency use authorisation to their vaccines.

“The applications are being examined on scientific basis, using the frameworks that are scientific, frameworks that are globally aligned and ensuring that the vaccine is safe, immunogenic adequately and effective in reducing the incidence of COVID-19 disease in people. This independent process is going on.

“I would like to note that when we talk about these processes, it is not one individual or three people. These are people who are scientists, epidemiologists, clinicians, scientists, pharamocologists, biologists. They take the decision based on science,” Paul said.

Speaking about adverse event following immunisation (AEFI), Paul said whenever a new medicine or vaccine is introduced in the country, there is a phase 4 stage of clinical trial which is also known as post-marketing surveillance.

The vaccine manufacturers during this phase monitor and track the effects of the vaccine systematically after it has been passed.

“If a vaccine or two comes after obtaining emergency use authorisation, you should have complete faith on the fact that the vaccine is scientifically proven, matches global standards, safe and effective,” he said.

Replying to a query about AEFI for COVID-19 vaccine, Paul informed, “This is an adult vaccine. Our AEFI system was targeted to children and women and those vaccinations take place in a certain way, starting with hospitals and then into the communities. But when we deal with adults, certain practical aspects have to be tackled.

“Secondly, these vaccinations are in multiple new platforms that bring in complexity. Further, if emergency use authorisation is given, it calls for more responsibility. Lastly, there are always new aspects, side-effects, situations that have to be kept in mind. Above all, a large number of beneficiaries and target-groups are to be tackled over a short period of time in a mission-mode,” he said.

“Therefore, there is a need to build on the standard principles of AEFI and make it specific to the fuller dimension of the requirements of this particular set of vaccines.”

On vaccine development, Paul said, this week, the DCGI has granted clearance for conduct of the phase 1 and 2 human clinical trials of the COVID-19 vaccine developed by the Pune-based Gennova Biopharmaceuticals Ltd in collaboration with HDT, USA.

“Important part of this vaccine is unlike Pfizer’s vaccine or others, this vaccine, if it comes into existence, will be maintainable at a normal cold chain conditions in a normal fridge. This is a big thing,” he said.

He said at this point, six vaccines are undergoing clinical trials in India. These are one developed by Bharat Biotech in collaboration with ICMR; second by Zydus Cadila; third one by Gennova; Oxford vaccine, trial of which is conducted by Serum Institute of India; Sputnik V vaccine which is being manufactured by Dr Reddy’s Lab, Hyderabad in collaboration with Russia’s Gamaleya National Centre; and the sixth one manufactured by Biological E Ltd, Hyderabad, in collaboration with MIT, USA.Biological E.

Related Posts

  • Pharma
  • December 21, 2024
  • 142 views
Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

Bengaluru: The Karnataka government has initiated prosecution against Paschim Banga Pharmaceuticals after five women died following C-section deliveries in Ballari district, where they were administered the company’s IV fluid. Health Minister…

  • Pharma
  • December 21, 2024
  • 196 views
NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

New Delhi:  The National Pharmaceutical Pricing Authority (NPPA) has notified ceiling price fixation of 13 scheduled formulations, retail price fixation of 65 new drugs against applications from individual companies, and…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

Telangana DCA Cracks Down On Illegal Drug Practices

Telangana DCA Cracks Down On Illegal Drug Practices

Pune: Two Arrested For Selling Illegal Steroid Injections In Gyms

Pune: Two Arrested For Selling Illegal Steroid Injections In Gyms

Serum To Make Chikungunya Vaccine In India

Serum To Make Chikungunya Vaccine In India